Allo IM

Module:
Profile management for patient and caregiver reported outcomes

Add-on:
Transportation API (e.g. Uber®) and Wearables API (e.g. FitBit®, Apple® Health)

Participants:
Alzheimer’s Patients

Status:
Launched September 2019

The study

Client: University of Arizona, Center for Innovation in Brain Science

This study is a national multi-site Phase 2 clinical trial to determine the effectiveness of Allopregnanolone, (ALLO), as a treatment for individuals with early-stage Alzheimer’s disease.

“The RESPOND HEALTH team worked closely with us to develop a novel strategy for Alzheimer’s patients and their caregivers. [The team] was amazing and generated progress in record time that allowed us to reach our goal. Data derived from the RESPOND HEALTH Platform has generated insights […] into outcomes relevant to therapeutic efficacy. Importantly, the RESPOND HEALTH group is an innovative team with exceptional brains and compassion committed to advancing precision medicine and health care in real people, in real time.”

Roberta Diaz Brinton, Ph.D.,
Director, Center for Innovation in Brain Science Professor Departments of Pharmacology and Neurology College of Medicine, University of Arizona